Background: Detailed molecular analyses of cells from rheumatoid arthritis (RA) synovium hold
Background
The destructive inflammatory environment in rheumatoid arthritis (RA) synovium results from the activity of various cell types, including synovial fibroblasts, macrophages, lymphocytes, osteoclasts, and vascular endothelial cells [1] [2] [3] [4] [5] . Multiple pathways can be targeted to treat rheumatoid arthritis, including inhibition of tumor necrosis factor (TNF) or interleukin-6 (IL- 6) signaling, blockade of T cell costimulation, depletion of B cells, and inhibition of the JAK/STAT pathway [6] . However, despite the advent of biologic therapies, up to ~2/3 of RA patients do not achieve sustained disease remission [7] , and there are no reliable biomarkers that serve to guide selection of specific therapeutic options for the individual patient. A more comprehensive interrogation of cells present in rheumatoid synovium may identify additional pathologic pathways targetable by therapeutics and aid in stratifying patients into disease subsets and treatment response categories based on informative biomarkers [8, 9] . Such studies have previously been limited by the lack of methods to simultaneously recover and assay the diversity of cell types in the synovium and by the challenge of applying high dimensional single cell analytics to sufficient numbers of patient samples. In addition, comparisons of identical cell lineages isolated from targeted tissues in patients with RA and other diseases such as systemic lupus erythematosus (SLE) have not been performed.
In recognition of these needs, the NIH Accelerating Medicines Partnership (AMP) RA/SLE network was assembled with the goal of generating detailed analyses of synovial tissue samples from a large number of RA patients. The RA Working Group of the AMP RA/SLE Network (or AMP RA network) has developed a pipeline to study RA synovial tissue samples through parallel high-dimensional analyses including mass cytometry, bulk RNA-seq of selected cell populations, and single cell RNA-seq. Mass cytometry can define the cellular landscape of tissues, while RNA sequencing delves deeper into the gene expression profile for each cell type. When performed at scale on a large patient cohort, these assays have the potential to aid in developing personalized therapeutic approaches for RA.
To amass an RA cohort of sufficient size, numerous clinical collection sites contributed synovial tissue samples. The network set out to develop a pipeline for uniform and reproducible sample handling involving cryopreservation of intact synovial tissue samples. The frozen tissue fragments were then shipped to a central processing site capable of performing multiple highdimensional analyses in parallel for each sample. The protocol was optimized for two sources of tissue: synovial biopsy obtained for research and clinically-indicated excision during arthroplasty.
Here, we report the AMP RA network protocol for dissociation and analysis of immune and stromal cells from cryopreserved synovial tissue by multiple high-dimensional technologies. We describe a consensus protocol for synovial tissue disaggregation that results in high yields of viable cells with preserved surface marker expression-for both larger arthroplasty and millimeter sized biopsy samples. We also describe an experimental pipeline to analyze each sample in parallel using single-cell RNA-seq and low-input bulk RNA-seq on selected populations, as well as mass cytometry with defined markers for synovial cells. This pipeline allows for cytometric identification and quantification of numerous immune and stromal cell populations, as well as robust transcriptomic analyses of small populations of cells from pathologic synovial samples. These methods are adaptable for use in multiple sites and have been adopted and utilized by the AMP RA network.
Methods

Human patient samples
Patients with RA fulfilled the ACR 2010 Rheumatoid Arthritis classification criteria or were identified by the participating site rheumatologist as having clinical RA [6] . A diagnosis of osteoarthritis (OA) was defined by the treating surgeon and confirmed by chart review. Synovial tissue samples were acquired by two different methods: arthroplasty and ultrasound-guided synovial biopsy. Arthroplasty samples were acquired after removal as part of standard of care at four U.S. institutions (Hospital for Special Surgery, NY, University California San Diego, CA, University of Pittsburgh, PA, and University of Rochester, NY). All synovial biopsy samples were acquired from clinically inflamed joints under research protocols at the University of Birmingham, UK and Barts & the London School of Medicine and Dentistry, UK. The study received institutional review board approval at each site.
Arthroplasty synovial tissue collection
Synovial tissue excised as standard of care during arthroplasty was transported from the operating room to a laboratory in ice-cold PBS. The tissue was identified as synovium by characteristic features: a fibrous or elastic tissue, pink or reddish in appearance. Small fragments (~1-2mm 3 ) were generated by dissecting with forceps or surgical scissors. Six fragments (~150mg total) across the tissue were randomly combined to make individual aliquots [10, 11] .
Synovial biopsy procedures
Synovial biopsy samples were obtained under ultrasound guidance by an experienced interventionist using either a needle biopsy or portal-and-forceps. For needle biopsy procedures, a 14G or 16G spring loaded Cook Quick-Core® Biopsy needle was used to obtain multiple fragments [12, 13] . For the portal-based approach, a portal (Merit Medical Prelude 7F) was initially inserted into the synovial cavity with multiple samples then retrieved using flexible 2.0-2.2mm forceps [14, 15] . Six biopsy fragments were randomly allocated per aliquot.
Synovial tissue cryopreservation and thawing
Synovial tissues were either (1) disaggregated immediately, followed by immediate cryopreservation of dissociated cells; with the dissociated cells cryopreserved or (2) cut into fragments that were cryopreserved for subsequent disaggregation at a central processing site.
Dissociated synovial cells were resuspended in CryoStor® CS10 (BioLife Solutions) at ~2 million cells/mL to viably freeze them. Intact synovial tissue samples were divided into fragments as described above and transferred to a cryovial (1.5mL, Nalgene) containing 1mL of CryoStor® CS10 for viable freezing. Cryovials were then placed into an insulated container with isopropanol in the bottom chamber for slow freezing (Mr. Frosty, Nalgene), which comprised incubation at 4°C for 10 minutes followed by one day at -80°C. The samples were then either shipped on dry ice or transferred into liquid nitrogen for long-term storage.
Synovial fragments were thawed by rapidly warming the cryovial in a 37°C water bath. The preservation media was filtered out through a 70µm strainer. The tissue was then rinsed through a series of incubations in a 6-well culture plate; 10 minutes in 10% FBS/RPMI at room temperature with intermittent swirling, a quick rinse in 10% FBS/RPMI and a final rinse in serum-free RPMI. Frozen synovial cells were thawed rapidly in a 37°C water bath and transferred into 20mL of 10% FBS/RPMI, centrifuged to pellet cells, and then resuspended in media for downstream analyses.
Dissociation of synovial tissue
Both arthroplasty and synovial biopsy samples were dissociated by a combination of enzymatic digestion and mechanical disruption with various test conditions described in the Results section. The final consensus AMP RA network enzyme digestion uses RPMI media with Liberase TL TM enzyme preparations (100µg/mL, Roche) and DNaseI (100µg/mL, Roche).
Arthroplasty tissue: To achieve consistent mechanical disruption and proteolytic enzyme exposure across a fragment of tissue, large synovial specimens (>150mg-gram) were cut into small fragments (~2mm 3 ) using surgical scissors. Mechanical disruption of arthroplasty samples (six tissue fragments totaling >500mg) was carried out by a gentleMACS dissociator system (Miltenyi) with the m_Spleen 04.01 setting, which involves churning and shredding in a sterile disposable tube. Enzymatic digestion was performed in RPMI medium at 37°C for 30 minutes. A large volume of 5% FBS/RPMI was then added to terminate the enzymatic reaction. The tissue was ground through a 70µm filter using the flat plastic end of a 3mL syringe plunger to disperse the remaining intact tissue and dispense dissociated cells.
Synovial biopsy tissue:
For the samples obtained by synovial biopsy, tissue fragments were minced into small fragments (~1mm 3 ) using a scalpel. Samples were then subjected to enzymatic digestion at 37°C while being exposed to continuous stirring in a U-bottom polystyrene tube (12 x 75mm) with a magnetic stir bar for 30 minutes. Half way through the enzymatic digestion, samples were passed gently through a 16-gauge syringe needle ten times for additional mechanical disruption.
RNA extraction from whole synovial tissue fragments
For samples used in the aforementioned dissociation protocol, synovial tissue fragments were also preserved for whole tissue RNA extraction. Three whole tissue replicates were collected for each sample, with six fragments placed into a cryovial containing 1mL of RNALater (Qiagen) and inverted three times. The cryovials were incubated overnight at 4°C. The next day, the cryovials were spun at ~1000xg for 30 seconds, most of the RNAlater was removed-leaving only enough RNAlater to cover the tissue. Cryovial were then place into -70°C for storage. For RNA extraction, samples were thawed and fragments transferred into RLT lysis buffer (Qiagen) + 1% b-mercaptoethanol (Sigma) and homogenized using a TissueLyser II (Qiagen) before RNA isolation using RNeasy columns.
Flow cytometry cell sorting
Synovial cell suspensions were stained with an 11-color flow cytometry panel designed to identify synovial stromal and leukocyte populations. Antibodies included anti-CD45-FITC (HI30), 
RNA sequencing
RNA from sorted bulk cell populations was isolated using RNeasy columns (Qiagen). RNA from up to 1000 cells was treated with DNase I (New England Biolabs), then concentrated using Agencourt RNAClean XP beads (Beckman Coulter). Full-length cDNA and sequencing libraries were prepared using the Smart-Seq2 protocol as previously described [16] . Libraries were sequenced on a MiSeq (Illumina) to generate 25 base pair, paired-end reads.
Single cell RNA-seq was performed using the CEL-Seq2 protocol (Illumina). Libraries were sequenced on a Hiseq 2500 (Illumina) in Rapid Run Mode to generate 76 base pair, paired-end reads. Mapping of reads to human reference transcriptome hg19 and quantification of mRNA expression levels was performed using RSEM [17] . Basic analyses of single cell RNA-seq data, including quantification of genes detected per cell, filtering of cells with less than 1000 detected genes, and principal components analyses, were performed.
Differential expression
To examine differential gene expression profiles between RA and OA synovial tissues processed through the consensus disaggregation protocol, tissue samples were collected from 10 RA and 10 OA patients. From these 20 patients, 2-8 replicates were generated per donor for a total of 87 samples. We performed differential expression analysis by fitting a linear mixed model to each gene, in which we controlled for unwanted technical variation with donor and site as random effects.
Gene ontology term enrichment analysis
We tested Gene Ontology (GO) enrichment with differentially expressed genes. We used Ensembl gene IDs downloaded on April 2016, including 9,797 GO terms and 15,693 genes. The minimal hypergeometric test was used to test for significance [18] .
Mass Cytometry
Synovial cells were resuspended in PBS/1%BSA with primary antibody cocktails at 1:100 dilution for 30 minutes (Additional file: Table 1 Calibration Beads (Fluidigm) as described [19] . viSNE analysis was performed using the Barnes-Hut SNE implementation on Cytobank (www.cytobank.org). Gated live cells (DNApositive, cisplatin-negative) were analyzed using all available protein markers. Biaxial gating was performed using FlowJo 10.0.7.
Results
Synovial tissue dissociation: optimizing cell yield and surface marker preservation
Laboratories within the AMP RA network (Fig. 1a) initially set out to collectively establish a standard operating procedure for isolating cells of differing lineages from synovial tissue. This protocol required balancing rigorous dissociation of stromal cells that adhere tightly to the tissue matrix, while minimizing perturbations and maintaining viability, RNA stability and key surface proteins required for downstream isolation and assays. In addition, methods were needed to handle both large arthroplasty samples and small synovial biopsy samples (Fig. 1b) .
Selection of methods for mechanical disruption
Pilot experiments across several sites suggested that various forms of mechanical disruption could be used, including manual inversion of the tube or incubation in a Stomacher ® 400
circulator. Dissociation using the GentleMACS was selected for arthroplasty as this method provided an automated and standardized protocol that could be implemented across laboratories (Fig. 1c) . However, dissociation of small synovial biopsy fragments (~0.5-1mm 3 )
using the GentleMACS system generated variable and insufficient yields, possibly due to cell retention in the dissociation container. Therefore, synovial biopsy samples were subjected to mechanical disruption by continuous magnetic stirring, combined with trituration through a syringe needle.
Enzymatic dissociation combined with mechanical disruption generates high cell yields
To test the impact of combining enzymatic treatment with mechanical dissociation, proteolytic enzymes were added to the media during mechanical dissociation. For the majority of tissue samples, higher cell yields were obtained when synovial fragments were incubated with enzyme in addition to mechanical disruption (Fig. 2a) . Importantly for highly adherent stromal (PDPN+CD45-) lineages, the proportion recovered increased with enzymatic digestion (Fig. 2b,   c ).
Proteolytic enzyme preparations differ in surface marker preservation
Focusing on highly purified enzyme formulations designed for standardized protocols, the consortium tested Liberase 
Optimization of proteolytic enzyme concentrations
To determine the optimal concentration of proteolytic enzyme for consistent cell recovery and reproducibility of downstream assays, four Network sites processed arthroplasty samples using three different Liberase TL TM concentrations, with three technical replicates for each concentration. In comparison to the 25 and 50µg/ml concentrations, the 100µg/ml concentration yielded the highest amount of intact RNA after tissue dissociation (Fig 2e) . In addition, synovial samples processed with 100µg/mL enzyme concentration demonstrated the lowest variance in RNA-seq gene expression across replicate samples, visually depicted in the principal component analysis (PCA) plots where distance between replicates is minimized with the 100µg/mL concentration (Fig. 2f) . Next, we computed the sum of squares within (SSW) to quantify replicate similarities within each of the three enzyme concentrations. Here, we also observed replicates processed with 100µg/mL had the least variation (Fig. 2g) .
To gain insight into the source of gene expression variation across synovial samples, we applied an analysis of variance (ANOVA) to each principal component to assess the contribution of the following sources: site, donor, and the potential impact of the dissociation process (Additional file: Supplementary Fig.1c ). The majority of gene expression variation associated with donor differences (PC1 and 2), which encompasses biological differences such as disease state. Site-specific collection and/or processing differences also contributed variation (PC1). Of note, the AMP network has designated a central processing site to eliminate site-specific dissociation effects.
Sample variability in PC3 and PC6 also related to gene expression differences that were identified in a separate RNAseq analysis comparing whole versus dissociated synovial preparations (Additional file: Supplementary Fig. 1c-e) . The dissociated versus whole tissue analysis was intended to identify dissociation-induced effects, however, involved mixtures of various cell types and, correspondingly, much of the gene expression differences indicated cell composition differences. These differences likely relate to differences in the preparation protocols; for example, adipocytes escape during spinning and aspiration steps in the dissociation protocol, while red blood cells may inadvertently be removed in whole tissue preparations during a salt solution incubation and subsequent aspiration. Nonetheless, outside of cell type-specific genes, there was an increase in stress response genes in dissociated cell preparations, similar to a previous report on dissociation-induced effects in single-cells [20] .
This included an upregulation in heat shock protein genes (HSP1A1, HSP6A, HSP90AA) and early response genes (FOS, JUN, ATF3) (Supplemental Fig. 1d-e) . Thus, synovial cells demonstrating specific upregulation in this signature could indicate a dissociation-induced gene expression pattern rather than a cell subset-specific program. For subsequent single-cell RNAseq studies, individual synovial cells with high levels of this stress response could either be removed from the analyses or the signature could be adjusted for computationally.
Overall, these results suggest that dissociation with 100µg/mL Liberase TL produces consistent and robust recovery of diverse synovial stromal and immune cell populations with the largest source of variation in the samples due to donor biological differences.
Development of Cryopreservation methods
Having established synovial dissociation methods, we then focused on establishing a strategy to analyze samples acquired at distant sites through a uniform high-dimensional analysis pipeline.
We first evaluated the feasibility of studying synovial cells cryopreserved after tissue dissociation. From three different arthroplasty samples analyzed either immediately after dissociation (fresh) or after freezing the cells in a cryopreservation solution for at least one day, comparable cell frequencies were extracted for synovial fibroblasts, monocytes, T cells, and B cells (Figure 3a ). This result suggested that synovial cells generally survive cryopreservation well, consistent with prior studies [5, 21, 22] .
In addition to cryopreserving dissociated synovial cells, we next evaluated the feasibility of cryopreserving intact synovial tissue fragments prior to dissociation. Notably, synovial biopsy tissue processed after cryopreservation yielded cells with comparable viability to paired tissue analyzed immediately after isolation (Fig. 3b) . In addition, flow cytometric analysis of cells from cryopreserved synovial tissue showed robust detection of stromal and hematopoietic cell populations, similar to fresh synovial tissue (Fig. 3c) . These results indicate that intact synovial tissue can be cryopreserved for subsequent cellular analyses.
We next examined whether application of the protocol implementing 100µg/mL of Liberase TL, mechanical disaggregation and viable freezing could detect robust expression pattern differences between dissociated synovial cells from tissues from patients with RA and osteoarthritis (OA). Importantly, an RNA-seq analysis of disaggregated total synovial cells demonstrated an up-regulation in RA of genes involved in immune processes, such as immunoglobulin binding, cellular response to molecules of bacterial origin, leukocyte chemotaxis and migration, cytokine production and antigen processing and presentation by MHC class II (Fig. 3d) .
High-dimensional assays of synovial cells
A goal of the AMP Network is to generate both mass cytometry and RNA-seq analyses of cells from cryopreserved synovial samples dissociated by the protocol described above. Acquisition of data for both of these technologies from the same synovial sample allows the coupling of Transcriptomes of single cells sorted from cryopreserved RA synovium were obtained by RNAseq through the CEL-Seq2 platform. High quality transcriptomes from both from single cell fibroblasts and leukocytes from RA synovium were generated, with fibroblasts generally yielding higher gene counts (Figure 6a ). Principal components analysis of single cells from an RA synovial sample separated the fibroblasts from the immune cells along PC1, and mostly separated macrophages from T and B lymphocytes along PC2 (Fig. 6b) . Importantly, single cells from each sorted cell population expressed markers expected for that cell type. For example, the podoplanin transcript was expressed primarily in fibroblasts, consistent with flow cytometry and mass cytometry data, while the CD14 transcript was identified in sorted macrophages, an expected finding since the cells were flow sorted by CD14 protein expression (Fig.6c) . Similarly, the CD3E transcript was uniquely detected in sorted T cells, while CD79A expression was unique to sorted B cells. These results indicate that high-quality transcriptomes can be generated from bulk populations and single cells obtained from cryopreserved RA synovial tissue samples.
Discussion
Here on a relatively large number of cells [5] . Transcriptomic analyses of sorted subpopulations can identify the cell types contributing specific gene expression signatures derived in the synovium, including signatures specific to RA synovium. Single cell transcriptomics allow a high-powered characterization of the heterogeneity of cells across a tissue [35] and within cell subsets that were previously classified as the same cell type [21, 22, 36] . We propose that integrating the multiple high-dimensional datasets acquired with this pipeline will reveal how distinct cell types contribute to specific aspects of RA pathology. Applied to a large patient cohort, these analyses have the potential to reveal functional pathologic markers that distinguish patients with distinct clinical trajectories and therapeutic responses [5] .
Implementing these technologies requires robust tissue processing protocols. The validation studies described here, which were carried out by a collaboration among laboratories with dissociation. This approach also eliminates site-specific processing effects, allowing samples to be processed at a central site that possesses multiple high-dimensional technologies, and to utilize batch processing of samples to minimize technical variation and confounding effects.
In an ongoing Phase 1 study, the AMP RA Network has implemented this synovial tissue pipeline in a pilot cohort of over 50 RA and OA patients with the goal of defining RA diseasespecific cellular populations and pathways. This will be followed by a Phase II study involving a much larger cohort of RA patients, including those with early disease, with a focus on identifying RA tissue biomarkers and novel tissue drug targets. A similar strategy of tissue cryopreservation has been adopted by the AMP for single cell transcriptomic analyses of kidney biopsy samples from patients with lupus nephritis, including development of a dissociation protocol optimized for human kidney tissue [37] . Although different tissues and cellular subsets may respond to cryopreservation differently, the strategy of analyzing cells from cryopreserved tissue appears readily adaptable to multi-center studies of tissues in other inflammatory diseases.
Conclusions
These studies demonstrate the feasibility and potential of analyzing viable cells from cryopreserved synovial tissue samples by multiple, complementary high-dimensional analyses.
Using an optimized dissociation protocol that provides high yields of viable cells with preserved cell surface and transcriptomic features, synovial tissue samples acquired across a multi-site network can be analyzed in a uniform way in order to identify dominant cell types and pathways, as well as to characterize previously unidentified cellular heterogeneity. Such approaches applied to large numbers of patients offer new opportunities to discover rheumatic disease biomarkers, targets for drug development, and molecular stratification of synovial pathology.
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